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Abstract. Background. Current classifications separate Bipolar (BD) from Major Depressive Disorder (MDD) 
based on polarity rather than recurrence. We aimed to determine bipolar/mixed feature frequency in a 
large MDD multinational sample with (High-Rec) and without (Low-Rec) >3 recurrences, comparing the two 
subsamples. Methods. We measured frequency of bipolarity/hypomanic features during current depressive 
episodes (MDEs) in 2,347 MDD patients from the BRIDGE-II-mix database, comparing High-Rec with Low-
Rec. We used Bonferroni-corrected Student’s t-test for continuous, and chi-squared test, for categorical 
variables. Logistic regression estimated the size of the association between clinical characteristics and High-
Rec MDD. Results. Compared to Low-Rec (n=1084, 46.2%), High-Rec patients (n=1263, 53.8%) were older, 
with earlier depressive onset, had more family history of BD, more atypical features, suicide attempts, 
hospitalisations, and treatment resistance and (hypo)manic switches when treated with antidepressants, 
higher comorbidity with borderline personality disorder, and more hypomanic symptoms during current 
MDE, resulting in higher rates of mixed depression according to both DSM-5 and research-based diagnostic 
(RBDC) criteria. Logistic regression showed age at first symptoms <30 years, current MDE duration ≤1 
month, hypomania/mania among first-degree relatives, past suicide attempts, treatment-resistance, 
antidepressant-induced swings, and atypical, mixed, or psychotic features during MDE to associate with 
High-Rec. Limitations. Number of MDEs for defining recurrence was arbitrary; cross-sectionality did not 
allow assessment of conversion from MDD to BD. Conclusions. High-Rec MDD differed from Low-Rec group 
for several clinical/epidemiological variables, including bipolar/mixed features. Bipolarity specifier and 
RBDC were more sensitive than DSM-5 criteria in detecting bipolar and mixed features in MDD. 
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Introduction. 
DSM-5 (American Psychiatric Association, 2013) separated Major Depressive (MDD) from Bipolar Disorders 
(BDs), allocating each condition an independent category. However, some patients with MDD may change 
diagnosis with time, developing (hypo)mania and converting to BDs (Kessing et al., 2017), while the 
opposite is nosographically impossible. Indeed, the diagnosis of a BD needs at least one hypomanic or 
manic episode in patient’s history. This kind of dichotomy, essentially based on the polarity of the episodes, 
might result in the neglect of other fundamental features of mood disorders such as recurrence, the core 
aspect in the original Kraepelinian definition of manicdepressive illness. 
There is a dearth of studies investigating the importance of recurrences on the course of MDD. Each new 
recurrence was found to increase probability of a new major depressive episode by 16% in a naturalistic 
study of MDD patients (Solomon et al., 2000). Many authors suggested the overall number of depressive 
episodes may be linked to the presence of a BD diathesis, regardless the occurrence of hypo/manic 
episodes (Andreasen et al., 1988; Benazzi, 2002; Ghaemi et al., 2002; Solomon et al., 2006; Goodwin and 
Jamison, 2007; Mitchell et al., 2008; Schaffer e al., 2010; Angst et al., 2011; Takeshima and Oka, 2013; 
Kessing et al., 2017). In this perspective, highly recurrent depression has shown some clinical characteristics 
that are nearer to BDs (Benazzi, 2002), like the similar tendency to develop hypomanic switches while on 
antidepressant drugs (Kupfer et al., 1988), and the presence of a BD family history (Akiskal and Benazzi, 
2006). Scholars differ in their definition of highly recurrent MDD. Benazzi (2002) and the Danish group 
(Kessing et al., 1998) considered a cutoff of more than four major depressive episodes (MDE), while Ghaemi 
et al. (2002) suggested the presence of more than three MDE as one of the diagnostic criteria for bipolar 
spectrum disorders. Most studies identified predictors of further recurrences by comparing MDD patients 
with BD patients (Kessing et al., 1998; Benazzi, 2002) and only few studies focused on large MDD samples 
(Solomon et al., 2000; Solomon et al., 2006; Mitchell et al., 2008). Moreover, while considering data on 
MDD and BD patients, diagnostic groups were infrequently matched by episode frequency (Benazzi, 2002). 
In order to explore the possible influence of recurrence in a large sample of MDD patients evaluated for the 
naturalistic BRIDGE-II-Mix study (Perugi et al., 2015a; 2015b; Popovic et al., 2015), we adopted a cut-off of 
more than three MDE. The primary objective of this study was to determine the frequency of a number of 
predefined bipolar features in MDD patients with (High-Rec) and without (Low-Rec) more than three 
recurrences. The secondary objective was to compare the rates of mixed features during current depressive 
episodes in High-Rec and Low-Rec patients. 
Materials and methods. The BRIDGE-II-MIX study, which is different from and does not overlap with the 
BRIDGE study (Angst et al., 2011), was a multinational (involving eight countries in three continents, i.e., 
Egypt and Morocco for Africa, Bulgaria, the Netherlands, Portugal, and Spain for Europe, and Russia and 
Turkey for both Asia and Europe), naturalistic (non-interventional), cross-sectional diagnostic effort 
conducted in 239 hospital-based or community centres by one psychiatrist in each centre with each centre 
reflecting the common psychiatric healthcare practices of each country. It had the objective to provide a 
reliable frequency estimate of mixed states in a large international sample of patients with major 
depressive episode (MDE). From June 2009 to July 2010, each centre enrolled for three consecutive months 
10-20 consecutive adult patients (aged ≥18 years) who sought help for a DSM-IV-TR MDE in three-month 
periods. The original study focused on mixed feature prevalence and definition in patients with MDE and 
analysed data of 2,811 patients with MDE, independently from whether they were diagnosed with major 
depressive disorder (MDD) or BD. From the 239 psychiatrists involved in the study, 237 returned their site 
questionnaire. The number of investigators per country ranged from 62 in Spain to 18 in Egypt. Practice 
settings were primary care (26%), community mental health services (23%), or hospital based (48%). The 
location of the practice was almost entirely urban. The mean proportion of patients who were hospitalised 
for the full sample was 26.0%. Demographic features were generally similar across countries. In this study 
we focus only on those 2,347 patients diagnosed with MDD. This is a post hoc analysis of the original 
dataset. 
Psychiatric comorbidities were established through DSM-IV-TR–based checklists focusing on 
alcohol/substance abuse/addiction, panic disorder, obsessive-compulsive disorder, social phobia, 
generalised anxiety disorder, eating disorders, borderline personality disorder, and attention 
deficit/hyperactivity disorder (ADHD). Patients presenting with an acute nonpsychiatric 
condition/emergency were excluded. 
The study was conducted according to the Declaration of Human Rights, as adopted by the 18th WMA 
General Assembly, Helsinki, Finland, June 1964, and subsequently amended by the 59th WMA General 
Assembly, Seoul, Republic of Korea, October 2008; http://www.wma.net); the Good Epidemiology Practice 
and the International Epidemiologic Association (IEA) European Federation Guidelines (http://ieaweb.org) 
were followed. Written, informed consent was obtained from each patient. In each country, the protocol 
was approved by local ethical committees. 
Data Collection 
Participating psychiatrists completed the same case report form in all centres, consisting in meeting 
inclusion criteria (DSM-IV-TR MDE) and collecting sociodemographic data, like age, gender, and marital 
status, and clinical data, like inpatient/outpatient status, history of psychiatric symptoms (mood changes, 
postpartum depression, and suicide attempts), and previous psychiatric hospitalisations. Noted were all 
features of the current depressive episode, including bipolar symptoms listed in the DSM-IV-TR diagnostic 
criteria for BD (American Psychiatric Association, 2000), known risk factors for BD, previous response to 
antidepressants, including reactions, psychiatric comorbidity, and current treatment, while global 
functioning was assessed through the Global Assessment of Functioning (GAF) scale (Endicott et al., 1976). 
The primary objective of the entire Bridge-II project was to establish in a mood disorder cohort the 
frequency of depressive mixed states, which was defined as the proportion of patients meeting: (1) DSM-5 
criteria for MDE with mixed features and (2) research-based diagnostic criteria (RBDC) (Angst et al., 2011). 
DSM-5 criteria require the presence for at least a week of an MDE and at least 3 of the following 
(nonoverlapping) hypomanic symptoms: (1) elevated, expansive mood, (2) inflated self-esteem or 
grandiosity, (3) more talkative than usual or pressure to keep talking, (4) flight of ideas or impression of 
racing thoughts, (5) increase in energy or goal-directed activity, (6) increased or excessive involvement in 
activities with a high potential for untoward consequences, and (7) decreased need for sleep. Since data 
collection took place before publication of the DSM- 5, we applied its criteria retrospectively, based on case 
report forms. 
RBDC were met when a MDE plus three of 14 hypomanic symptoms (i.e., irritable mood, emotional/mood 
lability, distractibility, psychomotor agitation, impulsiveness, verbal/physical aggression, racing thoughts, 
more talkative/speech pressure, hyperactivity, increased energy, risky behaviour, grandiosity, elation, and 
hypersexuality) co-occurred for at least one week. Revised BD-I specifier included manic episodes with the 
DSM-5 additional A criterion increased activity/energy without any exclusion criteria, while the revised BD-
II specifier included 1-3 days hypomanic episodes (Angst et al., 2013). 
Patients meeting DSM-IV-TR criteria for BD were excluded for the purpose of the current study, leaving a 
sample of patients with MDD. To this sample we applied the bipolarity specifier proposed by Angst et al. 
(2011; 2013). This “bipolarity” specifier attributes a diagnosis of “BD” to patients who experienced an 
episode of elevated mood or an episode of irritable mood or an episode of increased activity with at least 3 
of the symptoms listed under Criterion B of the DSM-IV-TR, associated with at least 1 of the 3 following 
consequences: (1) unequivocal and observable change in functioning uncharacteristic of the person’s usual 
behaviour, (2) marked impairment in social or occupational functioning observable by others, or (3) 
requiring hospitalisation or outpatient treatment. This specifier may apply to several subthreshold cases, 
which do meet neither full range of DSM/ICD symptom requirements nor duration criteria, thus 
overcoming the classical unipolar/bipolar dichotomy. This specifier requires no minimum duration and no 
exclusion of cases induced by drug treatment, recreational drug consumption or medical disease. 
Statistical Analysis 
Comparisons between the two sample groups, MDD patients with less than or equal to 3 lifetime episodes 
(Low-Rec) vs. MDD patients with more than 3 lifetime episodes (High-Rec), were assessed by using 
independent samples Student’s t-test for continuous variables and Chi-squared test for categorical 
variables. P-values, as well as odds ratios (OR) with 95% confidence intervals (CIs), were used for observed 
group differences. The analysis involved many tests of statistical significance, raising the potential of 
obtaining false-positive results (type I error). Consequently, we corrected for multiple comparisons, by 
employing a Bonferroni-corrected threshold for statistical significance, and divided the critical p-value (α) 
by the number of comparisons being made. In our study, 32 hypotheses were tested, thus the new critical 
p-value was α/32 = 0.0015. The statistical power of the study was then calculated based on this modified p-
value. 
Logistic regression was then used to calculate OR with 95% CI, so to estimate the size of the association 
between High-Rec and 8 a priori selected variables known to be associated with BD (Angst et al., 2011; 
Perugi et al. 2015a). These variables were age at first symptoms <30 years, duration of current depressive 
episode ≤1 month, current atypical, mixed, or psychotic depressive symptoms, current psychiatric 
comorbidities, history of suicide attempts, antidepressant treatment-resistance, antidepressants induced 
mania/hypomania or mood lability, and hypomania/mania among first degree relatives. MDD “predictors” 
for High-Rec were regarded as potential confounders and considered actual confounders if their 
distributions were substantially different in the two samples, regardless of statistical significance. The 
cutoff for statistical significance for logistic regression was set at p<0.05. All analyses were two-sided. When 
reporting logistic regression results, p<0.05 was considered as indicative of an association with High-Rec 
MDD, whereas p≥0.05 as indicative of no association with High-Rec MDD. Due consideration was given to 
associations at the edge of significance. 
All analyses were performed by using the statistical software SPSS Statistics for Macintosh, Version 20.0 
(IBM Corp., Armonk, NY, USA). 
Results 
Patients in the High-Rec group were more likely to be women, older, have had an earlier depressive onset 
than patients in the Low-Rec group, and to have more BD diagnosed in their relatives (Table 1). With 
respect to Low-Rec, High-Rec patients were more likely to have been diagnosed with MDD earlier, to have 
had their first MDE at a lower age than 30 years, to have more atypical features, to be more positive for a 
history of suicide attempts, to have more past suicide attempts, more hospitalisations, more global 
functioning impairment, and have a briefer duration of their current depressive episode and be more likely 
to have a current major depressive episode of less than one month (Table 1). They also had more 
borderline personality disorder comorbidity, whereas other comorbidities did not differ between High-Rec 
and Low-Rec. In particular, they did not differ for psychotic features(p=0.121), lifetime comorbid eating 
disorders (p=0.312), anxiety disorders (p=0.836), alcohol and/or substance use disorder (p=0.507), with 
borderline p-values (after the Bonferroni correction, p=0.0015) for OCD (p=0.003) and ADHD (p=0.004).. 
Regarding their previous treatments, High-Rec patients had used more antidepressant, antipsychotic, mood 
stabilizing drugs and anxiolytic drugs and more than three drugs per individual than the Low-Rec group. The 
two groups of patients did not differ for electroconvulsive therapy, in terms of mean number of sessions 
(p=0.431). The two groups differed also for their reactions to antidepressant drug treatment, in that 
patients in the High-Rec group had more manic- or hypomanic switches and antidepressant resistance 
(defined as non-response to at least two courses of different classes of antidepressants administered for 
adequate periods and at adequate doses [Souery et al., 1999]) than Low-Rec patients (Table 1). 
Of the 14 symptoms listed in the RBDC (hypomanic) criteria, patients in the High- Rec group had more 
symptoms than Low-Rec patients in 11 of these, i.e., emotional/mood lability, distractibility, impulsiveness, 
racing thoughts, talkativeness/pressure to keep talking, hyperactivity, increased energy, risky behaviour, 
grandiosity, euphoria, and hypersexuality (Table 2). 
High-Rec patients had more occurrences of RBDC BD specifiers and mixed depression according to the 
DSM-5 and RBDC criteria, in particular overall BD RBDC specifiers, bipolar I disorder RBDC specifiers, and 
bipolar II disorder RBDC specifiers, and also DSM-5 depressive mixed state specifiers and RBDC mixed 
depression criteria than Low-Rec patients (Table 3). 
In logistic regression, most variables were found to significantly predict a diagnosis of High-Rec MDD. When 
we estimated ORs and their respective CIs, age of first symptoms <30 years (p=0.004), duration of current 
depressive episode ≤1 month (p=0.028), current atypical, mixed, or psychotic depressive symptoms 
(p=0.005), history of suicide attempts (p=0.024), antidepressant treatment resistance (p=0.012), previous 
response of mania/hypomania or mood lability to antidepressants (p=0.015), and hypomania/mania among 
first degree relatives 2.09 (p=0.032) showed significantly higher occurrence in High-Rec than in Low-Rec. 
The only variable not associated with a diagnosis of High-Rec MDD was current psychiatric comorbidities 
(p=0.101) (Table 4). 
Discussion 
In our large sample of 2,347 patients diagnosed with MDD, we found subjects with more than 3 episodes 
(High-Rec) to differ from subjects with 1, 2 or 3 episodes (Low-Rec) for numerous sociodemographic and 
clinical characteristics. Independently from the diagnostic system adopted, High-Rec more frequently 
displayed bipolar/mixed features than Low-Rec. Notably in our sample, RBDC specifier showed significantly 
higher sensitivity in identifying bipolarity and mixed features than the DSM-5 criteria and mixed features 
specifier. These results are quite strong, as they resisted Bonferroni correction. As hypothesised, High-Rec 
were found to meet RBDC and DSM-5 mixed features more often than Low- Rec, to have more BD-In their 
family history, more hypomanic symptoms during MDE and suicidality, and more hypomanic switches and 
mood lability with antidepressants than Low-Rec. This result may be explained considering that RBDC 
criteria are wider and more inclusive than those of the corresponding DSM-5 specifiers. Our data point to 
the heterogeneity of MDD and to the importance of considering recurrence as an important clue as to the 
treatment to adopt, as antidepressant treatment may expose highly recurrent patients to more clinical risks 
than less recurrent ones. The fact that High-Rec patients were more likely to have a current major 
depressive episode lasting less than one month and had a briefer mean duration of their current MDE with 
respect to Low-Rec patients can be viewed as indicating that patients with more episodes were more 
sensitised to the reemergence of their depressive symptoms and sought help earlier than did people with 
less MDEs in their history. This may be taken as a hypothesis to test, although other interpretations are 
possible, like conditioning and kindling. 
Consistent with Benazzi (2002), who used a much smaller sample, we found High- Rec to be older than Low-
Rec and also to have an earlier onset, more familial occurrence of BD and more atypical features during 
MDE. Furthermore, similarly to Benazzi (2002), we did not find the two groups to differ for the presence of 
psychotic features. Comorbidity with Borderline Personality Disorder resulted more common in our High- 
Rec than in Low-Rec patients, while other comorbidities did not differ significantly between the two groups 
(only two showed “trends” toward significance; in fact, OCD and ADHD were significantly higher in High-Rec 
without the Bonferroni correction). It is important for clinicians to assess MDD patients for the presence of 
borderline personality disorder, as this comorbidity was previously found to share some features with our 
High- Rec sample, like early age at onset, highly recurrent course, mood switch while on antidepressants, 
high occurrence of family history for BD and of DSM-5 mixed features, and treatment-resistance (Perugi et 
al., 2015b). 
Splitting the MDD population into High-Rec and Low-Rec is not merely an academic concept; it might 
identify cases of greater proneness to convert to BD, thus having possible clinical and therapeutic 
implications. In fact, long-term antidepressant treatment has been shown to be associated with the 
conversion from MDD to BD (Baldessarini et al., 2013; Dudek et al., 2013). Despite most patients with MDD 
remain so after one or two years, about 15% of them converto to BD after one year and more than 20% 
after an additional year of follow-up (Kim et al., 2011). Mixed features and subsyndromal hypomanic 
symptoms during MDE were also found to be linked to conversion from MDD to BD (Zimmermann et al., 
2009; Dudek et al., 2010; Fiedorowicz et al., 2011; Faedda et al., 2015); in our study, eleven out of fourteen 
hypomanic symptoms explored during MDE were found to be significantly associated with High-Rec. 
Another study found lower age at onset to predict conversion from MDD to BD-I, and positive family history 
for BD to be associated with conversion from MDD to BD-II, which both match our data (Angst et al., 2005). 
Converters from MDD to BD had also higher numbers of hospitalisation and more treatment-resistance as 
our High-Rec sample (Li et al., 2012; Dudek et al., 2013). Furthermore, having more than three depressive 
episodes was associated with higher conversion rates (Dudek et al., 2013). Like in our sample, several 
studies found early onset of depression to be related to conversion from MDD to BD (Dudek et al., 2013; 
Takeshima and Oka, 2013; Tondo et al., 2014). 
As in our first BRIDGE-II reports on MDEs (Perugi et al., 2015a) and borderline personality disorder (Perugi 
et al., 2015b), RBDC was able to identify more bipolar/mixed features than DSM-5 in the MDD subsample 
(Table 3). This points to the need to adopt RBDC in evaluating patients with mood disorders, especially with 
MDD, and to distinguish them according to their total past mood episodes, so to better characterise their 
bipolar risk and treat them accordingly. 
In our sample we found a prominent use of antipsychotics, justified by the frequency of occurrence of 
psychotic and anxiety symptoms, benzodiazepine antianxiety agents, justified by the occurrence of anxiety 
symptoms which are core symptoms of mood disorders, and mood stabilisers, justified by treatment-
resistance and the need to protect MDD patients from suicide risk. In fact, lithium is the only drug that 
showed anti-suicidal properties independently from diagnosis (Baldessarini et al., 2006). 
Among the predefined bipolar features, logistic regression showed age at first symptoms <30 years, 
duration of current depressive episode ≤1 month, hypomania/mania among first degree relatives, history 
of suicide attempts, past history of antidepressant treatment-resistance and antidepressant induced 
mania/hypomania, and atypical, mixed, or psychotic features during the current depressive episode were 
associated with High- Rec. This finding is consistent with a study on polygenic loading of BD spectrum in 
MDD patients that identified characteristics like early onset, suicide attempt, recurrent and atypical 
depression, subclinical mania, subclinical psychosis, and severity (Wiste et al., 2014). The idea that in the 
MDD population there might be hidden a bipolar-prone population is an old-one and dates back to 
Kraepelin (1913), but more recently, Goodwin and Jamison (1990; 2007), Akiskal and Pinto (1999), and 
Akiskal and Benazzi (2006) refreshed it by putting forth more data and by reconsidering current 
classifications and enlarging diagnostic boundaries. 
Petra Zimmermann and colleagues (2009) identified a MDD subpopulation with increased subsyndromal 
bipolar symptoms and family history of BD that were more likely to convert to BD, thus questioning the 
diagnostic appropriateness of current practices and pointing to the heterogeneity of what we currently call 
MDD. These authors did not investigate recurrence of depression as a factor in conversion proneness, but 
Goodwin and Jamison (1990; 2007) promoted the view that recurrence rather than polarity may explain the 
heterogeneity of MDD and its belonging to the manic-depressive illness spectrum. Results from our study, 
along with other studies, which identified recurrence as a key factor in conversion from MDD to BD (Dudek 
et al., 2010; 2013; Takeshima and Oka, 2013; Tondo et al., 2014; Kessing et al., 2017), provide further 
support to this view. This has an important therapeutic implication, since the finding that antidepressants 
used in bipolar disorder do not increase switch rates (Sachs et al., 2007) in fact focused on just two 
antidepressants, so it is still controversial, while focusing on recurrence rates and treating patients 
according to the ISBD guidelines (Pacchiarotti et al., 2013) could represent a change in clinical practice that 
could improve patient management. Another way of approaching this concept is staging. Staging has been 
used in many medical and psychiatric conditions, including schizophrenia (McGorry, 2007) and bipolar 
disorder (Kapczinski et al., 2014; Vieta, 2015), and is now being introduced in depression (Guidi et al., 
2017). To some extent, our findings can also be conceptualised as emerging from a comparison between 
“early stage” versus “late stage” patients, but ideally a longitudinal design would have shed more light into 
this approach. The idea that mixed features, suicidality, and treatment response may be markers of late-
stage depression is worth pursuing. 
Limitations. The main limitation of this study was that the choice of the more than three MDEs cut-off 
criterion we adopted to define recurrence was literature-based, rather than obtained through the use of 
ROC (receiver operator characteristic). Furthermore, its cross-sectional nature prevents us from being able 
to assess conversion from MDD to BD. Moreover, clinical variables and treatment response were collected 
retrospectively, hence are susceptible to recall bias. However, our study has also remarkable strengths, 
represented by the large sample and the use of a MDD only population. 
Further research is needed focusing on recurrence rather than on polarity; other than clinical, genetic, 
neuroimaging, neuropsychological, neurobiological, and treatment response data are required to better 
characterise this issue. Our results are consistent with the existence of heterogeneous populations in the 
conundrum termed MDD. 
Conclusions. This study met both primary and secondary objectives, i.e., it determined frequency of bipolar 
features in High-Rec and Low-Rec MDD patients and compared the rates of mixed features in such patients. 
It aimed to identify a reliable clinical pattern in affective patients that would be based on recurrence, rather 
than on polarity; this would allow clinicians to adopt therapeutic strategies that would avoid transition 
from MDD to BD. For example, the use of antidepressants alone, without concomitantly using mood 
stabilisers, would unnecessarily expose people who have some BD risk to factors that would increase such 
risk. Presence of family history of BD, untoward reactions to antidepressants, irritability or resistance, 
suicidality, RBDC (hypo)manic symptoms and switch, and early onset characterise a different subset of 
recurrent MDD patients with greater severity and poorer outcome and should alert clinicians to adopt 
specific treatment strategies and precautions. Summarising, our data are consistent with highly recurrent 
MDD being related to bipolarity/mixed features and prompt us to take into consideration recurrence in 
treating patients. 
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 Table 1. Sociodemographic and clinical characteristics of the MDD sample subdivided according to 
number of lifetime episodes (>3, N = 1263, High-Rec; ≤3, N=1084, Low-Rec). P-values are shown with 
the Bonferroni-related cut-off, i.e., 0.0015. 
 
> 3 episodes 
(High-Rec) 
≤ 3episodes 
(Low-Rec) 
t-Test or 
chi-
square 
p OR (CI) 
Age, mean (SD) 47.6 (13.5) 40.4 (13.4) 0.207 
< 
.0001 
 
Age of onset, mean (SD) 31.8 (12.4) 35.3 (13.5) 11.01 
< 
.0001 
 
Gender, Female N (%) 933 (73.9) 704 (64.9) 22.03 
< 
.0001 
1.526 (1.279 to 
1.822) 
Family history, N (%) 
First-degree family history of 
BD 
211 (16.9) 97 (9.1) 30.49 
< 
.0001 
2.035 (1.576 to 
2.628) 
Course characteristics, N (%) 
Age 1
st 
depressive diagnosis, 
mean in years (SD) 
35.0 (12.2) 37.0 (13.1) 7.76 
< 
.0001 
 
Psychotic features 104 (8.2) 71 (6.5) 2.40 ns 
1.280 (0.936 to 
1.751) 
First MDE < 30 years 669 (53.0) 475 (43.8) 19.55 
< 
.0001 
1.444 (1.227 to 
1.700) 
Atypical features 106 (8.4) 46 (4.2) 16.58 
< 
.0001 
2.067 (1.448 to 
2.951) 
Current episode duration < 1 
month 
645 (51.1) 324 (29.9) 111.39 
< 
.0001 
3.001 (2.283 to 
4.541) 
History of suicide attempts 356 (28.2) 146 (13.5) 75.16 
< 
.0001 
2.522 (2.038 to 
3.121) 
Number of suicide attempts, 
mean (SD) 
8.11 (6.79) 3.13 (0.49) 1.01 
< 
.0001 
 
Memory disturbance 840 (66.5) 617 (56.9) 22.79 
< 
.0001 
1.503 (1.271 to 
1.777) 
Number of hospitalisations, 
mean (SD) 
2.6 (4.2) .301 (0.8) 574.63 
< 
.0001 
 
Duration current depressive 
episode, mean (SD) 
77.9 (94.9) 122.8 (153.3) 106.34 
< 
.0001 
 
GAF, mean (SD) 49.7 (12.7) 52.7 (12.6) 2.73 
< 
.0001 
 
Number of mood episodes, 
mean (SD) 
7.3 (7.1) 1.4 (.6) 446.74 
< 
.0001 
 
Lifetime comorbidity, N (%) 
OCD 78 (6.2) 38 (3.5) 8.93 ns 
1.816 (1.222 to 
2.701) 
Eating disorder 81 (6.5) 59 (5.5) 1.02 ns 
1.195 (.846 to 
1.689) 
ADHD 39 (3.1) 14 (1.3) 8.44 ns 
2.425 (1.309 to 
4.491) 
Anxiety disorder 354 (28.0) 308 (28.4) 0.04 ns 
0.981 (0.819 to 
1.175) 
Alcohol/substance use disorder 111 (8.8) 87 (8.0) 0.44 ns 
1.104 (.824 to 
1.480) 
Borderline personality disorder 90 (7.1) 38 (3.5) 14.83 
< 
.0001 
2.112 (1.432 to 
3.114) 
Previous treatments, n (%) 
Antidepressants 1130 (89.5) 824 (76.0) 75.75 
< 
.0001 
2.681 (2.136 to 
3.365) 
Antipsychotic agents 471 (37.3) 253 (23.3) 53.24 
< 
.0001 
1.953 (1.630 to 
2.341) 
Mood stabilisers 407 (32.2) 125 (11.5) 142.50 
< 
.0001 
3.648 (2.926 to 
4.548) 
ECT 20 (1.6) 13 (1.2) 0.62 ns 
1.326 (0.656 to 
2.677) 
BDZ 649 (51.4) 445 (41.1) 25.03 
< 
.0001 
1.518 (1.289 to 
1.788) 
> 3 drugs 493 (39.0) 212 (19.6) 105.3 
< 
.0001 
2.634 (2.182 to 
3.178) 
Past reactions to antidepressants, n (%) 
(Hypo)manic switches or Mood 
lability 
315 (24.9) 75 (6.9) 136.74 < 
.0001 
4.470 (3.423 to 
5.838) 
Treatment resistance 
494 (39.1) 165 (15.2) 164.89 < 
.0001 
3.578 (2.928 to 
4.373) 
      
Abbreviations: ADHD, attention deficit/hyperactivity disorder; BD, bipolar disorder; BDZ, benzodiazepines; 
CI, confidence interval; ECT, electroconvulsive therapy; GAF, Global Assessment of Functioning scale; 
High-Rec, high recurrence group; Low-Rec, low recurrence group; MDD, major depressive disorder; MDE, 
major depressive episode; OCD, obsessive-compulsive disorder; OR, odds ratio; SD, standard deviation. 
 
 
 
 
Table 2. RBDC (hypomanic) symptom distribution comparison between the High-Rec sample, with > 3 
lifetime episodes (N = 1263) and the Low-Rec sample, with ≤ 3 lifetime episodes (N = 1084). 
 > 3 episodes  
N (%) 
≤ 3 episodes  
N (%) 
chi-
square 
p OR (CI) 
Irritable mood 389 (30.8) 307 (28.3) 1.72 ns 1.126 (0.943 to 1.346) 
Emotional/mood 
lability 
366 (29.0) 248 (22.9) 11.24 = .001 1.375 (1.141 to 1.658) 
Distractibility 304 (24.1) 200 (18.5) 10.92 = .001 1.401 (1.147 to 1.712) 
Psychomotor 
agitation 
190 (15.0) 139 (12.8) 2.39 ns 1.204 (0.951 to 1.524) 
Impulsiveness 192 (15.2) 87 (8.0) 28.68 < .0001 2.054 (1.572 to 2.685) 
Aggression 
(verbal or 
physical) 
171 (13.5) 132 (12.2) .963 ns 1.129 (0.886 to 1.440) 
Racing thoughts 153 (12.1) 80 (7.4) 14.62 < .0001 1.730 (1.303 to 2.297) 
More 
talkative/pressure 
to keep talking 
159 (12.6) 65 (6.0) 29.37 < .0001 2.258 (1.671 to 3.050) 
Hyperactivity 92 (7.3) 35 (3.2) 18.74 < .0001 2.355 (1.581 to 3.506) 
Increased energy 109 (8.6) 42 (3.9) 21.91 < .0001 2.343 (1.626 to 3.378) 
Risky behaviour 98 (7.8) 43 (4.0) 14.86 < .0001 2.036 (1.409 to 2.943) 
Grandiosity 53 (4.2) 17 (1.6) 13.92 < .0001 2.749 (1.582 to 4.777) 
Euphoria 63 (5.0) 23 (2.1) 13.58 < .0001 2.422 (1.492 to 3.932) 
Hypersexuality 36 (2.9) 17 (1.6) 4.34 = .037 1.842 (1.028 to 3.298) 
 
 
 
 
Abbreviations: CI, confidence interval; High-Rec, high recurrence group; Low-Rec, low recurrence group; 
OR, odds ratio; RBDC, research-based diagnostic criteria (Angst et al., 2011; 2013). 
 
 
Table 3. Comparison of the distribution between the sample with > 3 lifetime episodes (High-Rec, N = 
1263) and that with ≤ 3 lifetime episodes (Low-Rec, N = 1084) of RBDC bipolar disorder specifiers and 
mixed depression according to the DSM-5 and to the RBDC criteria 
 
 
>3 
episodes 
N (%) 
≤3 episodes 
N (%) 
chi-square (df = 1) p 
OR 
(CI) 
Bipolar 
disorder 
specifier 
524 
(41.5) 
182 (16.8) 169.19 
< 
.0001 
3.514 
(2.893 
to 
4.269) 
Bipolar I 
disorder 
304 
(24.1) 
71 (6.5) 133.37 
< 
.0001 
4.523 
(3.442 
to 
5.943) 
Bipolar II 
disorder 
220 
(17.4) 
111 (10.2) 24.82 
< 
.0001 
1.849 
(1.448 
to 
2.361) 
Depressive mixed state 
DSM-5 
criteria 
100 
(7.9) 
31 (2.9) 28.32 
< 
.0001 
2.921 
(1.936 
to 
4.407) 
RBDC 
mixed 
363 
(28.7) 
228 (21.0) 18.4 
< 
.0001 
1.514 
(1.252 
to 
depression 1.832) 
Abbreviations: CI, confidence interval; df, degrees of freedom; DSM-5, Diagnostic and Statistical Manual of 
Mental Disorders, 5
th
 edition; High-Rec, high recurrence group; Low-Rec, low recurrence group; OR, odds 
ratio; RBDC, research-based diagnostic criteria (Angst et al., 2011; 2013). 
 
 
 
Table 4. Predictive factors for a diagnosis of MDD characterised by more than 3 lifetime 
episodes (High-Rec) 
 
Variables Odds Ratio [95% 
CI] 
p-value 
Age of first symptoms <30 years 5.02 [1.20-7.10] 0.004 
Duration of current depressive episode ≤1 month  2.28 [1.12-3.65] 0.027 
Current atypical, mixed, or psychotic depressive symptoms  4.96 [1.01-7.99] 0.005 
Current psychiatric comorbidities  1.76 [1.17-2.82] 0.101 
History of suicide attempts 2.35 [1.07-5.19] 0.024 
Antidepressant treatment resistance 3.15 [1.02-6.71] 0.012 
Previous response of mania/hypomania or mood lability to 
antidepressants  
3.10 [1.19-5.22] 0.015 
Hypomania/mania among first degree relatives 2.09 [1.16-6.01] 0.032 
Abbreviations: CI, confidence intervals; High-Rec, high recurrence group. Significant results in 
bold. 
 
 
 
Highlights 
 Separation between BD and MDD focus on polarity, not on recurrence 
 2,347 MDD patients from the BRIDGE-II-mix database assessed for mixed features 
 High-recurrence had more bipolar/mixed features than low-recurrence MDD patients 
 RBDC were more sensitive than DSM-5 in detecting bipolar/mixed features in MDD 
 
 
 
